
Pulmonary Infections in Adults
SECTION THREE
Pulmonary Infections in Immunocompromised Patients
This clinical content conforms to AAFP criteria for CME.
The following individual(s) in a position to control content for this activity have disclosed the following relevant financial relationships: Thomas M. File Jr, MD, disclosed a relationship with Merck & Co., Inc. related to its pneumococcal vaccine, a relationship with HealthTrackRx Molecular related to PCR-based tests, a relationship with Thermo Fisher Scientific Inc. related to PCR-based tests, a relationship with MicroGenDX related to advanced DNA diagnostics, a relationship with Shionogi Inc. related to cefiderocol (Fetroja), and a relationship with Paratek Pharmaceuticals, Inc. related to omadacycline (Nuzyra). Julio Alberto Ramirez, MD, disclosed a financial relationship with Pfizer Inc. related to consulting on its pneumococcal vaccine and a relationship with Dompé as a speaker on the topic of pathophysiology of pneumonia. All relevant financial relationships have been mitigated. All other individuals in a position to control content for this activity have indicated they have no relevant financial relationships to disclose.
Immunocompromised patients with pneumonia can have infection with both common pulmonary pathogens and opportunistic pathogens. A basic microbiological workup should be performed in all immunocompromised patients who are hospitalized and considered for outpatients. The need for a more extensive and invasive workup (eg, bronchoscopy for bronchoalveolar lavage transbronchial lung biopsy) should be individualized, considering risk factors for opportunistic pathogens. As part of treating immunocompromised patients with pneumonia, it is important to evaluate whether any immunosuppressive medications can be discontinued or decreased to improve the patient’s level of immunity. Empiric therapy for opportunistic pathogens should be considered in patients who have risk factors for a particular pathogen and when delaying appropriate therapy would increase mortality risk.
Case 3. JR is a 45-year-old man with rheumatoid arthritis that was diagnosed 5 years earlier. He is currently taking long-term high-dose corticosteroids (prednisone, 20 mg daily) and the tumor necrosis factor (TNF)-alpha inhibitor infliximab. JR has had progressive shortness of breath for the past week with nonproductive cough, low-grade fever, and fatigue.
Vital signs include temperature of 100.9°F (38.3°C), heart rate of 110/min, respiratory rate of 24/min, blood pressure of 120/80 mm Hg, and oxygen saturation of 88% on room air. Physical examination reveals bilateral fine crackles on auscultation and mild synovitis of the joints due to rheumatoid arthritis. Laboratory testing shows a white blood cell count of 6,500/μL (6.5 × 10 9/L), hemoglobin of 12 g/dL (120 g/L), and platelet count of 150,000/μL (150 × 10 9/L). Arterial blood gas testing shows a pH of 7.45, partial pressure of carbon dioxide of 35 mm Hg, partial pressure of oxygen of 55 mm Hg, and bicarbonate of 24 mEq/L (24 mmol/L). Chest radiography demonstrates diffuse interstitial infiltrates that are more pronounced in the perihilar regions. Chest computed tomography (CT) demonstrates ground-glass opacities, predominantly in the upper lobes.
Subscribe
From $350- Immediate, unlimited access to FP Essentials content
- 60 CME credits/year
- AAFP app access
- Print delivery available
Edition Access
$44- Immediate, unlimited access to this edition's content
- 5 CME credits
- AAFP app access
- Print delivery available